Segui questo link per vedere altri tipi di pubblicazioni sul tema: Leukemia Chemotherapy.

Articoli di riviste sul tema "Leukemia Chemotherapy"

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Leukemia Chemotherapy".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Narayanan, Geetha, M. T. Sugeeth, and Lali V. Soman. "Mixed Phenotype Acute Leukemia Presenting as Leukemia Cutis." Case Reports in Medicine 2016 (2016): 1–3. http://dx.doi.org/10.1155/2016/1298375.

Testo completo
Abstract (sommario):
Leukemia cutis (LC) is defined as infiltration of the skin by leukemic cells resulting in clinically recognizable cutaneous lesions. It is common in congenital leukemia and acute myeloid leukemia. However, LC has rarely been reported with mixed phenotypic acute leukemia (MPAL). We report the case of a lady who presented with erythematous papular and nodular lesions all over the body. Skin biopsy showed leukemic infiltration and bone marrow aspiration showed MPAL of the T/myeloid with monocytic differentiation lineage. This is the first report of an adult patient with MPAL of the T/myeloid with
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Dias, Sergio, Margaret Choy, Kari Alitalo, and Shahin Rafii. "Vascular endothelial growth factor (VEGF)–C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy." Blood 99, no. 6 (March 15, 2002): 2179–84. http://dx.doi.org/10.1182/blood.v99.6.2179.

Testo completo
Abstract (sommario):
Abstract Similar to solid tumors, growth of leukemias may also be angiogenesis dependent. Furthermore, tyrosine kinase receptors specific to endothelial cells are expressed on certain subsets of leukemias. We have previously demonstrated the existence of a VEGF/VEGFR-2 autocrine loop on leukemic cells that supports their growth and migration. Here, we demonstrate that in response to leukemia-derived proangiogenic and proinflammatory cytokines such as basic fibroblast growth factor and IL-1, endothelial cells release increasing amounts of another vascular endothelial growth factor (VEGF) family
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Wu, K. H., H. P. Wu, H. J. Lin, C. H. Wang, H. Y. Chen, T. Weng, C. T. Peng, and Y. H. Chao. "Concurrent hypopituitarism and leukemic retinopathy in a child with B-precursor acute lymphoblastic leukemia and isolated central nervous system relapse." Current Oncology 23, no. 4 (August 8, 2016): 431. http://dx.doi.org/10.3747/co.23.3006.

Testo completo
Abstract (sommario):
Hypopituitarism in leukemia is very rare. In addition, central nervous system (cns) relapse and leukemic retinopathy in childhood acute lymphoblastic leukemia (all) have declined with the use of modern systemic chemotherapy that includes cns prophylaxis. Here, we report the case of a 4-year-old girl who received chemotherapy and intrathecal therapy without cns radiation after a diagnosis of B-precursor all without cns involvement. Three months after chemotherapy completion, she presented with lower-extremity weakness and was diagnosed with an isolated cns relapse. Concurrent hypopituitarism an
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Falqués, Ton, Mattias Pilheden, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Axel Hyrenius Wittsten, Julhash U. Kazi, and Anna Hagstroem-Andersson. "Treatment Shapes Clonal Evolution and Resistance Patterns in Murine KMT2A-Rearranged Leukemia with Subclonal FLT3 N676K." Blood 138, Supplement 1 (November 5, 2021): 3354. http://dx.doi.org/10.1182/blood-2021-144760.

Testo completo
Abstract (sommario):
Abstract Our understanding of how individual mutations, whether present in all or just a fraction of the leukemia cells, affect cellular responses to therapy is limited. Leukemia mouse models provide a unique possibility to explore how therapy affects the evolution of genetically distinct clones and identify mechanisms of resistance allowing transfer to human disease. Herein, we studied how different therapies influenced survival, clonal evolution, and resistance patterns in mouse KMT2A-MLLT3 leukemia with subclonal FLT3 N676K. Bone marrow (BM) from a leukemia expressing KMT2A-MLLT3-mCherry in
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Moha, Rico. "Chemotherapy medication of Vincristine and Vinblastine." Cancer Research and Cellular Therapeutics 1, no. 1 (December 8, 2017): 01–02. http://dx.doi.org/10.31579/2640-1053/007.

Testo completo
Abstract (sommario):
Cancers treated with Vincristine and vinblastine include: acute leukemia, Hodgkin's and non- Hodgkin's lymphoma, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, Wilms' tumor, multiple myeloma, chronic leukemias, thyroid cancer, brain tumors, non-small cell lung cancer, bladder cancer, melanoma, and testicular cancer andIt is also used to treat some blood disorders. It is given by injection into a vein. Vincristine and vinblastine exhibit differential activity against tumors and normal tissues. In this work, a number of cultured cell lines were assayed for their sensitivity to the antiprolife
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Becker, Pamela S. "Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment." Scientific World Journal 2012 (2012): 1–4. http://dx.doi.org/10.1100/2012/856467.

Testo completo
Abstract (sommario):
Acute myeloid leukemia (AML) cells home to the endosteal region of the bone marrow. They interact with bone marrow stromal components including extracellular matrix proteins, glycosaminoglycans, and stromal cells, by which they derive proliferative and growth inhibitory signals. Furthermore, adhesion to marrow stroma confers chemotherapy drug resistance and thereby promotes leukemia survival. A subpopulation of the leukemic blasts, known as leukemia stem cells, that are capable of propagating the leukemia, remain sheltered in the bone marrow microenvironment, exhibit resistance to chemotherapy
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Frankfurt, Olga, and Martin S. Tallman. "Growth Factors in Leukemia." Journal of the National Comprehensive Cancer Network 5, no. 2 (February 2007): 203–15. http://dx.doi.org/10.6004/jnccn.2007.0020.

Testo completo
Abstract (sommario):
The role of myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, in the management of acute myeloid and acute lymphoblastic leukemias has been evaluated extensively in multiple clinical trials. Growth factors have been given before, concurrently, or sequentially with chemotherapy with the goal of reducing the duration of neutropenia and consequently the incidence and severity of infections, and improving the rate of remissions and overall survival. They also have been studied as chemotherapy-sensitizing agents in an effort
Gli stili APA, Harvard, Vancouver, ISO e altri
8

DeAngelo, Daniel J., Eytan M. Stein, and Farhad Ravandi. "Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?" American Society of Clinical Oncology Educational Book, no. 36 (May 2016): e302-e312. http://dx.doi.org/10.1200/edbk_161258.

Testo completo
Abstract (sommario):
Acute myeloid leukemia (AML) is an acquired disease characterized by chromosomal translocations and somatic mutations that lead to leukemogenesis. Systemic combination chemotherapy with an anthracycline and cytarabine remains the standard induction regimen for “fit” adults. Patients who achieve complete remission generally receive postinduction therapy with cytarabine-based chemotherapy or an allogeneic bone marrow transplant. Those unfit for induction chemotherapy are treated with hypomethylating agents (HMAs), low-dose cytarabine, or they are offered supportive care alone with transfusions a
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Kumar, Bijender, Marvin Orellana, Jamison Brooks, Srideshikan Sargur Madabushi, Liliana E Parra, Darren Zuro, Qiong Wang, Ching-Cheng Chen, and Susanta Hui. "Leukemia Cells Remodel Adipocyte Niches and Their Progenitor Functions to Generate Leukemia Favoring Niche." Blood 132, Supplement 1 (November 29, 2018): 1294. http://dx.doi.org/10.1182/blood-2018-99-115689.

Testo completo
Abstract (sommario):
Abstract Increasing evidence suggests that the cancer cells take shelter in different osteoblastic and adipocytic niches, where they hide from chemotherapy and continue to survive. As yet, how leukemia cells alter the bone marrow (BM) adipocytic niches to facilitate their expansion and assist them in evading chemotherapy is unclear. We have previously shown that the acute myeloid leukemia (AML) cells directly or through their exosomes, reprogram BM osteoblastic niche which facilitates their expansion and suppress normal hematopoiesis(Kumar B et al, Leukemia 2018,32(3):575-587). In this study ,
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Hapsari, Happy Indri. "INCREASING KNOWLEDGE OF PARENTS IN CARE OF THE SIDE EFFECTS OF CHEMOTHERAPY IN LEUKEMIA CHILDREN THROUGH BOOKLET IN DR. MOEWARDI GENERAL HOSPITAL SURAKARTA." Jurnal Ilmiah Kesehatan Media Husada 8, no. 2 (October 24, 2019): 39–47. http://dx.doi.org/10.33475/jikmh.v8i2.196.

Testo completo
Abstract (sommario):
Leukemia is the number one cancer that attacks children aged 0 to 18 years. Parents who have children with leukemia will experience a heavy burden in caring for children. Health education is one way for nurses to ease the burden of parents in finding information about leukemia. The use of booklets has long been known as a medium in health education, where effectiveness is very significant in increasing parental knowledge. The purpose of the study: to determine the effect of health education with booklets on the level of knowledge of parents in caring for leukemic children who are on chemothera
Gli stili APA, Harvard, Vancouver, ISO e altri
11

Kampa-Schittenhelm, Kerstin M., Charles D. Lopez, and Marcus Schittenhelm. "ASPP2 Expression In Acute Leukemia Modulates Response to Therapy." Blood 116, no. 21 (November 19, 2010): 3143. http://dx.doi.org/10.1182/blood.v116.21.3143.3143.

Testo completo
Abstract (sommario):
Abstract Abstract 3143 Acute myeloid leukemias (AML) remain difficult to treat and therapy outcome is far from satisfactory for most disease subgroups. Inactivation of the p53 tumor suppressor pathway by mutation is a frequent event in many cancers that promotes tumorigenesis and resistance to chemotherapy. Although p53 mutations are rare in AML it is not well studied whether the p53 pathway is influenced by other mechanisms instead. ASPP2 (Apoptosis Stimulating Protein of p53 2) is a highly regulated member of a family of p53-binding proteins that enhance apoptosis at least in part through st
Gli stili APA, Harvard, Vancouver, ISO e altri
12

Ptasiewicz, Maja, Paweł Maksymiuk, and Renata Chałas. "Changes of Dentition State in Leukemic Patients during Chemotherapy." International Journal of Environmental Research and Public Health 18, no. 15 (August 2, 2021): 8193. http://dx.doi.org/10.3390/ijerph18158193.

Testo completo
Abstract (sommario):
A number of systemic diseases including hematological disorders have manifestations in the oral cavity region. These manifestations may often represent early signs of the underlying hematopoietic disease and occur frequently in leukemia. Despite the fact that leukemia has long been known to be associated with oral health deterioration, the available literature on this topic consists mostly of case reports, without data to conclude these. The aim of the study was to assess dentition state in leukemic patients during one cycle of chemotherapy and its correlation with blood parameters. The study
Gli stili APA, Harvard, Vancouver, ISO e altri
13

Swatler, Julian, Laura Turos-Korgul, Ewa Kozlowska, and Katarzyna Piwocka. "Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias." Cancers 13, no. 6 (March 10, 2021): 1203. http://dx.doi.org/10.3390/cancers13061203.

Testo completo
Abstract (sommario):
Both chronic myeloid leukemia and acute myeloid leukemia evade the immune response during their development and disease progression. As myeloid leukemia cells modify their bone marrow microenvironment, they lead to dysfunction of cytotoxic cells, such as CD8+ T cells or NK cells, simultaneously promoting development of immunosuppressive regulatory T cells and suppressive myeloid cells. This facilitates disease progression, spreading of leukemic blasts outside the bone marrow niche and therapy resistance. The following review focuses on main immunosuppressive features of myeloid leukemias. Firs
Gli stili APA, Harvard, Vancouver, ISO e altri
14

Swatler, Julian, Laura Turos-Korgul, Marta Brewinska-Olchowik, Sara De Biasi, Wioleta Dudka, Bac Viet Le, Agata Kominek, et al. "4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells." Blood Advances 6, no. 6 (March 17, 2022): 1879–94. http://dx.doi.org/10.1182/bloodadvances.2021006195.

Testo completo
Abstract (sommario):
Abstract Chronic and acute myeloid leukemia evade immune system surveillance and induce immunosuppression by expanding proleukemic Foxp3+ regulatory T cells (Tregs). High levels of immunosuppressive Tregs predict inferior response to chemotherapy, leukemia relapse, and shorter survival. However, mechanisms that promote Tregs in myeloid leukemias remain largely unexplored. Here, we identify leukemic extracellular vesicles (EVs) as drivers of effector proleukemic Tregs. Using mouse model of leukemia-like disease, we found that Rab27a-dependent secretion of leukemic EVs promoted leukemia engraftm
Gli stili APA, Harvard, Vancouver, ISO e altri
15

Buss, Eike C., Alexander Kalinkovich, Amir Schajnovitz, Orit Kollet, Ayelet Dar, Melania Tesio, Stefan Fruehauf, et al. "In Vivo Mobilization of Leukemic Human Precursor-B-ALL Cells by the CXCR4-Antagonist AMD3100 Is Via Secretion of SDF-1 and Synergistically by Catecholamine Action." Blood 112, no. 11 (November 16, 2008): 1920. http://dx.doi.org/10.1182/blood.v112.11.1920.1920.

Testo completo
Abstract (sommario):
Abstract Introduction Mobilization of leukemic cells from the bone marrow (BM) to the circulation in order to better kill them with DNA damaging chemotherapy agents is emerging as a new experimental therapeutic intervention, however the mechanism is not entirely clear. Currently CXCR4-antagonists such as the mobilizing agent AMD3100 (AMD) are becoming available for clinical usage. The aim of this study is to explore mechanisms of human precursor-B-ALL cell mobilization from the BM in a functional, pre-clinical immune deficient mouse model. Methodology Immunodeficient mice were stably engrafted
Gli stili APA, Harvard, Vancouver, ISO e altri
16

Lam, Wilbur A., Michael J. Rosenbluth, and Daniel A. Fletcher. "Chemotherapy Exposure Decreases Leukemia Cell Deformability as Determined by Atomic Force Microscopy: Implications for Leukostasis in Acute Leukemia." Blood 108, no. 11 (November 1, 2006): 2359. http://dx.doi.org/10.1182/blood.v108.11.2359.2359.

Testo completo
Abstract (sommario):
Abstract Leukostasis, a life-threatening complication of acute leukemia, occurs when leukemia cells obstruct the circulation of vital organs like the brain and lungs leading to intracranial hemorrhage or respiratory failure. Although the pathophysiology of leukostasis is poorly understood, an elevated concentration of circulating leukemia cells, pathologic adhesion, and decreased cell deformability are thought to play significant roles. Clinical deterioration can occur soon after chemotherapy is initiated, suggesting that chemotherapy itself may be a risk factor for leukostasis. To investigate
Gli stili APA, Harvard, Vancouver, ISO e altri
17

Subramaniam, Priya, K. Girish Babu, and J. Nagarathna. "Oral Manifestations In Acute Lymphoblastic Leukemic Children Under Chemotherapy." Journal of Clinical Pediatric Dentistry 32, no. 4 (July 1, 2008): 319–24. http://dx.doi.org/10.17796/jcpd.32.4.0p1462t621w20477.

Testo completo
Abstract (sommario):
Leukemia is a common malignancy seen in young children and acute lymphoblastic leukemia (ALL) accounts for 75% of all leukemias. Advances in the treatment regimen include multi-agent chemotherapy and central nervous system directed radiotherapy. Immune suppression caused due to disease and therapy makes these children more prone to bacterial, fungal infections and at times reactivation of viral diseases. Hence, the present study was taken to assess, the oral conditions among ALL children during chemotherapy.
Gli stili APA, Harvard, Vancouver, ISO e altri
18

Dunussi-Joannopoulos, Kyriaki, Werner Krenger, Howard J. Weinstein, James L. M. Ferrara, and James M. Croop. "CD8+ T Cells Activated During the Course of Murine Acute Myelogenous Leukemia Elicit Therapeutic Responses to Late B7 Vaccines After Cytoreductive Treatment." Blood 89, no. 8 (April 15, 1997): 2915–24. http://dx.doi.org/10.1182/blood.v89.8.2915.

Testo completo
Abstract (sommario):
Abstract We have previously shown in a murine acute myelogenous leukemia (AML) model that leukemic mice can be cured with a B7 vaccine if immunized early in the disease and that CD8+ T cells are necessary for tumor rejection. However, when B7 vaccine is administered 2 weeks after leukemia inoculation, the effect is only prolonged survival, ending in death virtually of all the mice. To distinguish between tumor kinetics and tumor-induced immunosuppression as potential mechanisms eliminating the therapeutic potential of late B7 vaccines, we performed in vitro T-cell studies during leukemia progr
Gli stili APA, Harvard, Vancouver, ISO e altri
19

Diamandidou, E., A. U. Buzdar, T. L. Smith, D. Frye, M. Witjaksono, and G. N. Hortobagyi. "Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience." Journal of Clinical Oncology 14, no. 10 (October 1996): 2722–30. http://dx.doi.org/10.1200/jco.1996.14.10.2722.

Testo completo
Abstract (sommario):
PURPOSE Adjuvant chemotherapy for breast cancer has been the routine practice in the past decade. A number of studies have observed an increased incidence of treatment-related leukemias following chemotherapy with alkylating agents and/or topoisomerase II inhibitors. We evaluated the incidence of treatment-related leukemias in breast cancer patients treated in four adjuvant and two neoadjuvant chemotherapy trials at The University of Texas M.D. Anderson Cancer Center. PATIENTS AND METHODS Between 1974 and 1989, 1,474 patients with stage II or III breast cancer were treated in six prospective t
Gli stili APA, Harvard, Vancouver, ISO e altri
20

Sohn, CC, DW Blayney, JL Misset, G. Mathe, G. Flandrin, EM Moran, FC Jensen, CD Winberg, and H. Rappaport. "Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: association with human retroviruses." Blood 67, no. 4 (April 1, 1986): 949–56. http://dx.doi.org/10.1182/blood.v67.4.949.949.

Testo completo
Abstract (sommario):
Abstract We report two cases of a T cell lymphoproliferative disease not previously described, with cytologic and clinical features similar to those associated with Galton's “prolymphocytic” leukemia (PL). Our patients, like those with Galton's PL, had massive splenomegaly and minimal or absent hepatomegaly and lymphadenopathy. In contrast, however, our patients had leukopenia, as well as low percentages of leukemic cells in the peripheral blood and in the bone marrow. In splenic imprints, the nuclear chromatin pattern of most of the leukemic cells was intermediate between those of mature lymp
Gli stili APA, Harvard, Vancouver, ISO e altri
21

Sohn, CC, DW Blayney, JL Misset, G. Mathe, G. Flandrin, EM Moran, FC Jensen, CD Winberg, and H. Rappaport. "Leukopenic chronic T cell leukemia mimicking hairy cell leukemia: association with human retroviruses." Blood 67, no. 4 (April 1, 1986): 949–56. http://dx.doi.org/10.1182/blood.v67.4.949.bloodjournal674949.

Testo completo
Abstract (sommario):
We report two cases of a T cell lymphoproliferative disease not previously described, with cytologic and clinical features similar to those associated with Galton's “prolymphocytic” leukemia (PL). Our patients, like those with Galton's PL, had massive splenomegaly and minimal or absent hepatomegaly and lymphadenopathy. In contrast, however, our patients had leukopenia, as well as low percentages of leukemic cells in the peripheral blood and in the bone marrow. In splenic imprints, the nuclear chromatin pattern of most of the leukemic cells was intermediate between those of mature lymphocytes a
Gli stili APA, Harvard, Vancouver, ISO e altri
22

Zeng, Zhihong, Yue Xi Shi, Ismael J. Samudio, Rui-Yu Wang, Xiaoyang Ling, Olga Frolova, Mark Levis, et al. "Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML." Blood 113, no. 24 (June 11, 2009): 6215–24. http://dx.doi.org/10.1182/blood-2008-05-158311.

Testo completo
Abstract (sommario):
Abstract SDF-1α/CXCR4 signaling plays a key role in leukemia/bone marrow microenvironment interactions. We previously reported that bone marrow–derived stromal cells inhibit chemotherapy-induced apoptosis in acute myeloid leukemia (AML). Here we demonstrate that the CXCR4 inhibitor AMD3465 antagonized stromal-derived factor 1α (SDF-1α)–induced and stroma-induced chemotaxis and inhibited SDF-1α–induced activation of prosurvival signaling pathways in leukemic cells. Further, CXCR4 inhibition partially abrogated the protective effects of stromal cells on chemotherapy-induced apoptosis in AML cell
Gli stili APA, Harvard, Vancouver, ISO e altri
23

YORIMITSU, Seiichi. "Induction Chemotherapy for Acute Leukemia." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 97, no. 3-4 (1985): 277–87. http://dx.doi.org/10.4044/joma1947.97.3-4_277.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
24

YORIMITSU, Seiichi. "Induction Chemotherapy for Acute Leukemia." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 97, no. 3-4 (1985): 289–99. http://dx.doi.org/10.4044/joma1947.97.3-4_289.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
25

HARA, Masamichi. "Induction chemotherapy for acute leukemia." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 98, no. 3-4 (1986): 243–54. http://dx.doi.org/10.4044/joma1947.98.3-4_243.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
26

HARA, Masamichi. "Induction chemotherapy for acute leukemia." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 98, no. 3-4 (1986): 255–64. http://dx.doi.org/10.4044/joma1947.98.3-4_255.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
27

ONO, RYUZO. "Blood. Chemotherapy of the leukemia." Nihon Naika Gakkai Zasshi 86, no. 3 (1997): 477–80. http://dx.doi.org/10.2169/naika.86.477.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
28

Pieters, Rob, Annemiek M. Schans-Dop, A. Ine Brenk, Annette HM Taets Amerongen, and Anjo JP Veerman. "OSTEONECROSIS FOLLOWING CHEMOTHERAPY FOR LEUKEMIA." European Journal of Haematology 43, no. 3 (April 24, 2009): 262–64. http://dx.doi.org/10.1111/j.1600-0609.1989.tb00295.x.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
29

Chasen, Martin R., and Geoffrey Falkson. "Leukemia after Chemotherapy for Cancer." Cancer Biotherapy 8, no. 2 (January 1993): 115–22. http://dx.doi.org/10.1089/cbr.1993.8.115.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
30

Adra, Nabil, Hamid Sayar, and Lawrence H. Einhorn. "Chemotherapy-Related Chronic Myelogenous Leukemia." JAMA Oncology 2, no. 3 (March 1, 2016): 391. http://dx.doi.org/10.1001/jamaoncol.2015.4837.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
31

Lu, Hongbo, Zhihong Zeng, Yuexi Shi, Sergej Konoplev, Donald Wong, Marina Konopleva, and Michael Andreeff. "Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist CTCE-9908 Enhances Chemotherapy-Induced Apoptosis in AML." Blood 112, no. 11 (November 16, 2008): 2415. http://dx.doi.org/10.1182/blood.v112.11.2415.2415.

Testo completo
Abstract (sommario):
Abstract The chemokine receptor CXCR4 is critically involved in the migration of hematopoietic cells towards the stromal derived factor (SDF-1α)-producing bone marrow microenvironment. We and others have previously demonstrated that stroma/leukemia interactions mediate protection of leukemic cells from chemotherapy-induced apoptosis (Konopleva, Leukemia 2002). Using a peptide analog of SDF-1α designated CTCE-9908, we tested the hypothesis that CXCR4 inhibition interferes with stromal/leukemia cell interactions resulting in increased sensitivity to chemotherapy. Our results showed that CTCE-990
Gli stili APA, Harvard, Vancouver, ISO e altri
32

Barve, Vega, Shah, Ghare, Casson, Wunderlich, Siskind, and Beverly. "Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia." Cells 8, no. 11 (October 25, 2019): 1322. http://dx.doi.org/10.3390/cells8111322.

Testo completo
Abstract (sommario):
Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-R leukemias are uniquely dependent on the epigenetic function of the H3K79 methyltransferase DOT1L, which is misdirected by MLL-FPs activating gene expression, driving transformation and leukemogenesis. Given the functional necessity of these leukemias to maintain adequate methylation potential allowing aberrant activating histone methylation
Gli stili APA, Harvard, Vancouver, ISO e altri
33

Ratain, MJ, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C. Skosey, S. Purl, PC Hoffman, J. Wade, and JW Vardiman. "Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung." Blood 70, no. 5 (November 1, 1987): 1412–17. http://dx.doi.org/10.1182/blood.v70.5.1412.1412.

Testo completo
Abstract (sommario):
Abstract Combination chemotherapy is frequently used in the therapy of advanced non-small-cell lung cancer (NSCLC), but late complications are rarely recognized because of the short survival of most patients. Of 119 patients with advanced NSCLC treated with cisplatin and other drugs, four patients developed acute nonlymphocytic leukemia (ANLL). All four patients received etoposide and cisplatin with or without vindesine. Leukemia was diagnosed at 13, 19, 28, and 35 months after start of treatment. Three patients had morphologic and/or cytogenetic features of acute leukemia with significant mon
Gli stili APA, Harvard, Vancouver, ISO e altri
34

Ratain, MJ, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C. Skosey, S. Purl, PC Hoffman, J. Wade, and JW Vardiman. "Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung." Blood 70, no. 5 (November 1, 1987): 1412–17. http://dx.doi.org/10.1182/blood.v70.5.1412.bloodjournal7051412.

Testo completo
Abstract (sommario):
Combination chemotherapy is frequently used in the therapy of advanced non-small-cell lung cancer (NSCLC), but late complications are rarely recognized because of the short survival of most patients. Of 119 patients with advanced NSCLC treated with cisplatin and other drugs, four patients developed acute nonlymphocytic leukemia (ANLL). All four patients received etoposide and cisplatin with or without vindesine. Leukemia was diagnosed at 13, 19, 28, and 35 months after start of treatment. Three patients had morphologic and/or cytogenetic features of acute leukemia with significant monoblastic
Gli stili APA, Harvard, Vancouver, ISO e altri
35

Ueda, Yutaka. "Problems in anti-leukemic drugs chemotherapy of childhood acute leukemia." Journal of Nippon Medical School 54, no. 6 (1987): 573–80. http://dx.doi.org/10.1272/jnms1923.54.573.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
36

Cavanna, Luigi, Daniele Vallisa, Michele Di Stasi, Fabio Fornari, Elisabetta Buscarini, Claudio Schena, Giuseppe Civardi, Giorgio Sbolli, Raffaella Berte, and Luigi Buscarini. "Acute Myelocytic Leukemia and Chronic Myelomonocytic Leukemia Simultaneously with Resectable Breast Cancer: A Report of two Cases." Tumori Journal 78, no. 5 (October 1992): 356–58. http://dx.doi.org/10.1177/030089169207800516.

Testo completo
Abstract (sommario):
This report describes 2 patients who developed acute myelocytic leukemie (AML) type M2 and chronic myelomonocytic leukemia (CMML) of the FAB classification, respectively 2 months and 2 weeks after diagnosis of operable breast cancer. The patient with AML showed pancytopenia 2 months before the diagnosis of AML, had a normal karyotype, and showed a good response to chemotherapy. The patient with CMML had a normal karyotype, and she was treated with hydroxyurea and supportive therapy. The 2 patients had no previous exposure to irradiation or cytotoxic therapy. These cases show that breast cancer
Gli stili APA, Harvard, Vancouver, ISO e altri
37

Milojkovic, Dragana, and Jane F. Apperley. "How I treat leukemia during pregnancy." Blood 123, no. 7 (February 13, 2014): 974–84. http://dx.doi.org/10.1182/blood-2013-08-283580.

Testo completo
Abstract (sommario):
Leukemia in pregnancy remains a challenging therapeutic prospect. The prevalence is low at ∼1 in 10 000 pregnancies, and as a result data are limited to small retrospective series and case reports, rendering evidence-based recommendations for management strategies difficult. The management of the leukemias in pregnancy requires close collaboration with obstetric and neonatology colleagues as both the maternal and fetal outcomes must be taken into consideration. The decision to introduce or delay chemotherapy must be balanced against the impact on maternal and fetal survival and morbidity. Inva
Gli stili APA, Harvard, Vancouver, ISO e altri
38

Shi, Yang, and Endi Wang. "Blastic Plasmacytoid Dendritic Cell Neoplasm: A Clinicopathologic Review." Archives of Pathology & Laboratory Medicine 138, no. 4 (April 1, 2014): 564–69. http://dx.doi.org/10.5858/arpa.2013-0101-rs.

Testo completo
Abstract (sommario):
Blastic plasmacytoid dendritic cell neoplasm is a rare entity grouped with the acute myeloid leukemia–related precursor neoplasms in the 2008 World Health Organization classification. It was previously postulated to originate from natural killer cells, T cells, or monocytes but is now believed to arise from the plasmacytoid dendritic cell. The pathogenesis of blastic plasmacytoid dendritic cell neoplasm is not well understood, although the neoplasm demonstrates frequent deletion of tumor suppressor genes, including RB1, CDKN1B, CDKN2A, and TP53. Blastic plasmacytoid dendritic cell neoplasm is
Gli stili APA, Harvard, Vancouver, ISO e altri
39

Yeasmin, S., K. Nakayama, M. Ishibashi, A. Oride, A. Katagiri, I. N. Purwana, K. Iida, N. Nakayama, H. Ishikura, and K. Miyazaki. "Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review." International Journal of Gynecologic Cancer 18, no. 6 (2008): 1371–76. http://dx.doi.org/10.1111/j.1525-1438.2007.01185.x.

Testo completo
Abstract (sommario):
Alkylating agents have strong leukemogenic potential. There are a number of recent acute myeloid leukemia (t-AML) cases related to previous paclitaxel exposure. These leukemias tend to be of aggressive subtypes with long-latency periods. Unlike previously reported cases, the present case was of the secondary acute megakaryoblastic myeloid leukemia (AML M7) subtype. Additionally, it did not harbor a translocation in chromosome 19. A 73-year-old woman was diagnosed with t-AML M7 with antecedent myelodysplasia. Leukemia followed a second induction of paclitaxel- and carboplatin-based chemotherapy
Gli stili APA, Harvard, Vancouver, ISO e altri
40

Freireich, Emil J. "Prevention of chemotherapy-induced leukemia and of leukemia relapses." Medical Oncology and Tumor Pharmacotherapy 8, no. 3 (September 1991): 155–58. http://dx.doi.org/10.1007/bf02987173.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
41

Eshghabadi, M., A. M. Shojania, and I. Carr. "Isolated granulocytic sarcoma: report of a case and review of the literature." Journal of Clinical Oncology 4, no. 6 (June 1986): 912–17. http://dx.doi.org/10.1200/jco.1986.4.6.912.

Testo completo
Abstract (sommario):
Granulocytic sarcoma (GS) is an extramedullary tumor composed of granulocytic precursor cells. The tumor usually develops during the course of myelogenous leukemia or myeloproliferative disorders and may represent the initial manifestation of leukemia. Rarely, GS is recognized as an isolated tumor without any evidence of leukemia. However, in such cases, leukemia generally develops within 1 to 2 years of the diagnosis of GS. We are reporting a case of a 45-year-old woman who was diagnosed as having an isolated GS of the right breast in August 1980. She was treated with a partial mastectomy fol
Gli stili APA, Harvard, Vancouver, ISO e altri
42

Zhang, Ziting, Kun Yang, and Han Zhang. "Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?" Cancers 14, no. 22 (November 17, 2022): 5655. http://dx.doi.org/10.3390/cancers14225655.

Testo completo
Abstract (sommario):
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of hematological malignancy characterized by its high heterogeneity and potentially life-threatening clinical features. Despite the advances in risk stratification and therapeutic management of T-ALL, patients often suffer from treatment failure and chemotherapy-induced toxicity, calling for greater efforts to improve therapeutic efficacy and safety in the treatment of T-ALL. During the past decades, increasing evidence has shown the indispensable effects of leukemia-initiating cells (LICs) and leukemic niches on T-ALL initia
Gli stili APA, Harvard, Vancouver, ISO e altri
43

Chistyakova, Natalia V. "Ophthalmic manifestation of leukemia." Ophthalmology journal 9, no. 2 (June 15, 2016): 81–99. http://dx.doi.org/10.17816/ov9281-99.

Testo completo
Abstract (sommario):
This paper includes a literature review on the ophthalmic manifestations of leukemia. Various eye disorder types in leukemia with concurrent anemia, hypoxia, increased blood viscosity, as well as the compression of tissues by tumor cells conglomerates and/or presence of direct leukemic infiltration were considered. Ophthalmic diseases in patients with hematological malignancies may occur due to opportunistic infections and the impact of such treatments as chemotherapy, radiotherapy and bone marrow transplantation. Reliable estimation of eye involvement rates in leukemic process is difficult, a
Gli stili APA, Harvard, Vancouver, ISO e altri
44

Jabbour, Elias, Susan O’Brien, Farhad Ravandi, and Hagop Kantarjian. "Monoclonal antibodies in acute lymphoblastic leukemia." Blood 125, no. 26 (June 25, 2015): 4010–16. http://dx.doi.org/10.1182/blood-2014-08-596403.

Testo completo
Abstract (sommario):
Abstract With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity. When added to frontline chemotherapy, rituximab, an antibody di
Gli stili APA, Harvard, Vancouver, ISO e altri
45

V.E., Mayorova,, Mollaev, M.D., Vikhreva, P.N., Kulakovskaya, E.A., Pershin, D.E., Kibardin, A.V., Maschan, M.A., and Larin, S.S. "ANTIBODY-FREE CHIMERIC FLT3-CAR RECEPTOR FOR TARGETING THE FLT3 RECEPTOR, A MARKER OF POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA." CARDIOMETRY, no. 24 (November 30, 2022): 63–65. http://dx.doi.org/10.18137/cardiometry.2022.24.conf.35.

Testo completo
Abstract (sommario):
Therapy in acute myeloid leukemia (AML) usually begins with a course of induction chemotherapy using anthracyclines and cytarabine to eliminate blast cells. Chemotherapy is a necessary step in preparing a patient for transplantation of donor hematopoietic stem cells (HSCs). However, leukemia stem cells often show their chemoresistance and initiate the AML recurrence. Specific elimination of the leukemic stem cells during the preparation of a patient for HSC transplantation may reduce the probability of recurrence. For this purpose, an active development of chimeric antigen receptors (CAR) to a
Gli stili APA, Harvard, Vancouver, ISO e altri
46

Journal, Baghdad Science. "Evaluation of ELectrolytes in Adult Patients with Acute Leukemia before and after Chemotherapy." Baghdad Science Journal 10, no. 2 (June 2, 2013): 362–67. http://dx.doi.org/10.21123/bsj.10.2.362-367.

Testo completo
Abstract (sommario):
Abstract:Leukemia is a cancer of early blood forming cells. Most of them are cancers of white blood cells , however some leukemias start in other blood cell types.Electrolytes have modulatory effects on several biological mechanisms in the body namely as stabilizers,element of structures, essential element for hormonal function and also co-factors for a number of enzymes.In this study serum electrolytes levels were measured in patients with acute leukemia (AL) disorders before and after chemotherapy(anthracycline, doxorubicin, cytarabine ,prednisone, vincristine and doxorubicin) during one mon
Gli stili APA, Harvard, Vancouver, ISO e altri
47

Shahjahani, Mohammad, Amirreza Abroun, Najmaldin Saki, Seyed Mohammad Bagher Mohammadi, and Hadi Rezaeeyan. "STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia." Laboratory Medicine 51, no. 4 (December 20, 2019): 345–51. http://dx.doi.org/10.1093/labmed/lmz074.

Testo completo
Abstract (sommario):
Abstract Background Based on the results of multiple studies, multiple signaling pathways is a major cause of resistence to chemotherapy in leukemia cells. Signal transducer and activator of transcription 5 (STAT5) is among these factors; it plays an essential role in proliferation of leukemic cells. Methods We obtained the materials used in our study via PubMed search from 1996 through 2019. The key search terms included “STAT5,” “acute leukemia,” “leukemogenesis,” and “mutation.” Results On activation, STAT5 not only inhibits apoptosis of leukemic cells via activating the B-cell lymphoma 2 (
Gli stili APA, Harvard, Vancouver, ISO e altri
48

Lotem, J., and L. Sachs. "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells." Blood 80, no. 7 (October 1, 1992): 1750–57. http://dx.doi.org/10.1182/blood.v80.7.1750.1750.

Testo completo
Abstract (sommario):
Abstract Transforming growth factor-beta 1 (TGF-beta 1) induces cell death in myeloid leukemia by apoptosis. In the M1 myeloid leukemia, this induction of apoptosis was inhibited by granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6) and to a lesser extent by IL-1 alpha. IL-3 and stem cell factor/mast cell growth factor (SCF) showed only a marginal effect, and granulocyte-macrophage and macrophage CSFs (GM-CSF and M-CSF, respectively) were inactive. The induction of apoptosis by TGF-beta 1 in a different myeloid leukemia (7-M12) was inhibited by GM-CSF and IL-3 but not by the
Gli stili APA, Harvard, Vancouver, ISO e altri
49

Lotem, J., and L. Sachs. "Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells." Blood 80, no. 7 (October 1, 1992): 1750–57. http://dx.doi.org/10.1182/blood.v80.7.1750.bloodjournal8071750.

Testo completo
Abstract (sommario):
Transforming growth factor-beta 1 (TGF-beta 1) induces cell death in myeloid leukemia by apoptosis. In the M1 myeloid leukemia, this induction of apoptosis was inhibited by granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6) and to a lesser extent by IL-1 alpha. IL-3 and stem cell factor/mast cell growth factor (SCF) showed only a marginal effect, and granulocyte-macrophage and macrophage CSFs (GM-CSF and M-CSF, respectively) were inactive. The induction of apoptosis by TGF-beta 1 in a different myeloid leukemia (7-M12) was inhibited by GM-CSF and IL-3 but not by the other cy
Gli stili APA, Harvard, Vancouver, ISO e altri
50

Coustan-Smith, Elaine, Jose Sancho, Frederick G. Behm, Michael L. Hancock, Bassem I. Razzouk, Raul C. Ribeiro, Gaston K. Rivera, et al. "Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia." Blood 100, no. 1 (July 1, 2002): 52–58. http://dx.doi.org/10.1182/blood-2002-01-0006.

Testo completo
Abstract (sommario):
Abstract Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10 000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identifie
Gli stili APA, Harvard, Vancouver, ISO e altri
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!